Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT, page-36

interesting set of presentations and announcements over a few days, all slightly the same and different.

Still think the results are good to me; if result like these were with a big pharma (and better reaction from the FDA) the story on our SP would be totally different. the vote going with us..and then denied goes heavily against us.

the follow suggest to me that Nov (still well mentioned in any reporting with no comment by Novo) and MSB might do a confirmatory trial together.. and with FDA imput to the changing endpoint out comes. hope its a short one. but where should it be held as death rates decline in certain countries due to better treatment, can it be held in a country with high death rates??
Also a point Si made about wanting the full cohort and completed even if it was found to be OE....was to get the numbers for the 12 month followup....and asessment against long Covid.... a forgotten topic and possibly the 'other' pandemic yet to be had.
The topic is swallowed up some what by Vac talk, but occassional we do see a mention it...with the uncertainty with Vaccines and coverage time, effectiness as some countries are finding like indonesia china and alike with health care professional dying from covid after fully vaccination against severe ill and death ie not working. but they were using different vaccines too. But that chatter is because noone really knows what the delta alpha or other mutants still to come will provide in the way of long term illness....as said not too long ago, everything from brain to heart were some of the side effects..... covid patients with no symptoms ended up in wheel chairs months later....
also was said by the experts that it was likely any mutants would be less harmful as they spread losing thier potency ...the opposite is happening.
"
 Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps
 Confirmatory Phase 3 trial in COVID-19 ARDS patients < 65 years of age with
dexamethasone, explore additional remestemcel-L dosing regimens for patients with ARDS
≥ 65 years of age
"